Navigation Links
Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer

research agreement with Peregrine Pharmaceuticals Inc.

Number 4091: Enhancing the immunogenicity of glioma cells with anti- phosphatidylserine antibody, Jin He, Troy A. Luster, Philip E. Thorpe. UT Southwestern Medical Center, Dallas, TX, Apr 17, 2007, 8:00 AM - 12:00 PM EDT

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs for HCV infection and a range of solid cancers in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that pre-clinical animal model efficacy results will not correlate to efficacy studies in human clinical trials, the risk that future studies will not support a potential role for anti-PS therapies, such as bavituximab, as an immune-enhancing cancer vaccine, and the risk that future studies may not support the initiation of human clinical trials. It is important to note that the company'
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
(Date:11/27/2009)...PRNewswire/--ACUOTECHNOLOGIES,developersofhigh-per...ontoolsandservices,ispleasedtoannouncethattheUnite...pplicationforan"AssetCommunicationFormatwithinaCom....patenttoitsportfolioofintellectualproperty.Ingene...,stechnologyanduseofassetmetainformationtocontrolr...
(Date:11/25/2009)...Newswire-FirstCall/--HeskaCorporation(HSKA);("Hesk...altyproductstotheveterinaryindustry,announcedtoday...plyofbloodgasproductsandaffiliatedconsumablesforth....com/cgi-bin/prnh/20000622/HESKALOGO ) ,, "Hesk...dofadvancedpoint-of-carediagnostics,"commentedMich...
(Date:11/25/2009)...ire/--BioTrendsResearchGroup,Inc.releasedWave1ofit...amulti-phasesyndicatedmarketresearchprojecttrackin...ductlaunchthroughthefirstsixmonthsofavailability.E...rom75uniqueDermatologistsandqualitativeinformation...ra,obstaclestouse,typicalpatienttypes,productperce...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 1DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 2DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 3Government of Canada announces funding for research on the H1N1 flu virus 8732 1Government of Canada announces funding for research on the H1N1 flu virus 8732 2Ludwig Institute of Cancer Research Ltd Brussels Branch Issues Statement Concerning Prospect Therapeutics Incs GCS 100 Molecule 48071 1Ludwig Institute of Cancer Research Ltd Brussels Branch Issues Statement Concerning Prospect Therapeutics Incs GCS 100 Molecule 48071 2
...x S.A.,(Eurolist: COX) today announced that Merck ... planned clinical studies, in mild to moderate,hyp...tive agreement to,develop new nitric oxide-donatin...technology. Three drug candidates have now been se... of which two have completed initial,dose ranging ...
...n Prevention Business, DUBLIN, Ohio, May 12 Card...vices that improve the safety and,productivity of ...acquisition of assets of privately held Enturia, I...ucts sold under the ChloraPrep(R) brand name., Ch... hospitals and,surgery centers as a patient preope...
Other Medicine Technology:NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Cardinal Health Completes Enturia Acquisition 2
(Date:11/27/2009)...cialist manufacturers who use medical load cells a...of dollars by bringing in technology partner Flint... of pro-active medical manufacturers are calling i...f their projects, ensuring that progress will not ...entially outdated technology. , ...
(Date:11/26/2009)...g tetrathiomolybdate (TM) has been shown in studie...se, a disease caused by an overload of copper, and...ery little, however, is known about how the drug w...y Northwestern University researchers now has prov...ucture of TM bound to copper-loaded metallochapero...
(Date:11/26/2009)...earch Triangle Dental (RTDental), a leading dental...nnounced the expansion of its services to include ...g Macmillan. , Durham,... to announce that Dr. Doug Macmillan, an experienc...tional advanced training seminar. RTDental’...
(Date:11/25/2009)....25/PRNewswire-FirstCall/-- OnyxPharmaceuticals,I...hosttwoinvestoreventsinDecember: ,, ASHBriefi... ,, Principalinvestigatorswilldiscussdatapres...ractorymultiplemyeloma,asfeaturedatthe51stAmerican...inNewOrleans,LA.Theteleconferencewillbeginat9:00a....
(Date:11/25/2009)...ewswire-USNewswire/--TheBlackAIDSInstituterecently...adershipfor2010. ,, ThenewBoardMembersareahighl...y,law,finance,governmenthealthprograms,editorial,a...iderangeofpersonalbackgroundsincludingbothheterose...lves,andrepresentingmultipleagegroups. ,, (Phot...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2
... of Switzerland finds children who are exposed to ... also have asthma or allergies. Researchers had pa...ires// regarding asthma and hay fever. They also t...r levels of endotoxin, a component of the cell wal...
...hen it comes to health issues. In California, trav...o smoke for residents. Environmental tobacco smoke...nge of adverse health effects - from exacerbation ...sity of California have studied a group of 200 peo...
... with mood disorders who have attempted suicide ar...ll. The link is especially strong among those who ...suffer from mood disorders themselves. Resear...people at especially high risk. Researchers from t...
...tion may unclog a mechanical heart pump, reconditi...researcher from University Hospital in Germany,// ...ous problem for heart failure patients who receive...pumping ability of a heart that can't dynamically ...
...preventable cause of death. Turning off the televi...w study finds the more an adolescent watches telev...//The risk of disease increases the earlier in lif...ising on television, smoking is still widespread o...
...th a higher dose of radiotherapy, with weekends o...involves a daily dose of radiotherapy five days a ...n found from a more intensive programme known as C... computer models, they suggested that a higher dos...
Other Medicine News:
Gamma GT (GLUPA)
Creatine Kinase (CK-NAC) SZASZ
Cholesterol (CHOD-PAP) (DIMENSION)
Cholesterol (Liquid)
Medicine Products: